Featured Publications
IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma
Wong J, Roy S, McNiff J, Xu M. IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma. The American Journal Of Surgical Pathology 2023, 47: 1425-1431. PMID: 37767989, DOI: 10.1097/pas.0000000000002133.Peer-Reviewed Original ResearchMeSH KeywordsHumansInterferon Regulatory FactorsInterleukin-3 Receptor alpha SubunitPanniculitisPanniculitis, Lupus ErythematosusConceptsSubcutaneous panniculitis-like T-cell lymphomaLupus erythematosus panniculitisPanniculitis-like T-cell lymphomaCase of SPTCLT-cell lymphomaPlasmacytoid dendritic cell differentiationPlasmacytoid dendritic cellsExpression of IRF8Dendritic cell differentiationCharacteristic curve analysisImportant clinical implicationsRegulatory factor 8Dendritic cellsCutaneous biopsyLymphoid aggregatesDiagnostic challengeImmunohistochemical panelImmunohistochemical expressionCD123CD20Distinct patientsClinical implicationsSubcutaneous fatDiagnostic testsPositive markersGlobal assessment of IRF8 as a novel cancer biomarker
McQuaid DC, Panse G, Wang WL, Pinkus GS, Katz SG, Xu ML. Global assessment of IRF8 as a novel cancer biomarker. Human Pathology 2022, 122: 1-10. PMID: 35085599, PMCID: PMC10621657, DOI: 10.1016/j.humpath.2022.01.004.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorHumansInterferon Regulatory FactorsNeoplasmsRetrospective StudiesSarcomaConceptsBlastic plasmacytoid dendritic cell neoplasmInterferon regulatory factor 8Myeloid sarcomaDifferential diagnosisPlasmacytoid dendritic cell neoplasmDesmoplastic small round cell tumorSmall round cell tumorTriple-negative breast cancerStrong uniform expressionDendritic cell neoplasmBroad differential diagnosisNegative breast cancerRound cell tumorAbsence of CD34IHC expression patternsAcute monocytic leukemiaNovel immunohistochemical markerTypes of cancerRegulatory factor 8Cancer Genome AtlasNovel cancer biomarkersRetrospective studySynovial sarcomaCell tumorsPleomorphic sarcoma
2023
IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression
Tang H, Panse G, Braddock D, Perincheri S, Xu M, McNiff J. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. Journal Of Cutaneous Pathology 2023, 50: 595-600. PMID: 37082914, DOI: 10.1111/cup.14439.Peer-Reviewed Original ResearchMeSH KeywordsDendritic CellsHematologic NeoplasmsHumansInterferon Regulatory FactorsInterleukin-3 Receptor alpha SubunitMaleMiddle AgedSkin NeoplasmsConceptsBlastic plasmacytoid dendritic cell neoplasmPlasmacytoid dendritic cell neoplasmDendritic cell neoplasmPunch biopsy specimenBiopsy specimenCell neoplasmsCase of BPDCNUseful markerTumor cellsTCL-1 expressionAtypical mononuclear cellsBone marrow involvementDiffuse dermal infiltrateDendritic cell lineagePotential diagnostic pitfallRegulatory factor 8TCL-1BPDCN casesCD123 expressionMarrow involvementDermal infiltrateCutaneous nodulesMyelodysplastic syndromeSkin nodulesMononuclear cells
2022
Response to Letter to the Editor: IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias but does not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells
Xu ML, Katz SG. Response to Letter to the Editor: IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias but does not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells. The American Journal Of Surgical Pathology 2022, 46: 1739-1739. PMID: 36040049, DOI: 10.1097/pas.0000000000001961.Peer-Reviewed Original ResearchMeSH KeywordsDendritic CellsHumansInterferon Regulatory FactorsLeukemia, Monocytic, AcuteMonocyte-Macrophage Precursor CellsIRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas
McQuaid DC, Katz SG, Xu ML. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. American Journal Of Clinical Pathology 2022, 158: 173-176. PMID: 35460405, PMCID: PMC10664184, DOI: 10.1093/ajcp/aqac044.Peer-Reviewed Original Research
2021
IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias
Katz SG, Edappallath S, Xu ML. IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias. The American Journal Of Surgical Pathology 2021, 45: 1391-1398. PMID: 34172624, DOI: 10.1097/pas.0000000000001765.Peer-Reviewed Original ResearchConceptsChronic myelomonocytic leukemiaAcute monocytic leukemiaBlast countCore biopsyMyelomonocytic leukemiaBone marrowPredictive valueMonocytic leukemiaBone marrow core biopsiesCases of AMoLMarrow core biopsiesAcute myeloid leukemia subtypesExpression of IRF8Acute myeloid leukemiaTrephine core biopsiesReliable surface markersDendritic cell progenitorsNegative predictive valuePositive predictive valuePotential biomarker candidatesBlast increaseMonocytic blastsUseful immunostainsBlast percentageReactive monocytosis